Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
NRx Pharmaceuticals filed a formal investor presentation deck as an exhibit to be used in meetings with investors and analysts. The presentation provides a strategic update on the company's pharmaceutical pipeline and business operations.
Perdoceo Education Signs $224M M&A Deal with South University Savannah, LLC
Perdoceo Education Corporation entered into a definitive agreement to acquire 100% of South University for an initial cash payment of $150 million, plus $18 million in deferred consideration and up to $56 million in performance-based earn-outs. South University is a leading health sciences-focused institution with 11 campus locations and approximately 10,500 students, generating $291 million in 2025 revenue. The transaction is expected to close as early as April 2027 and will expand Perdoceo's graduate health sciences and academic program offerings.
Telomir Pharmaceuticals announced positive preclinical in-vitro research findings demonstrating that its compound Telomir-Zn inhibited cell growth in both human and canine osteosarcoma models. The study, conducted with The Ohio State University, showed consistent anti-tumor activity at low drug concentrations, supporting a potential parallel development pathway for veterinary and human oncology indications.
Counterparty
The Ohio State University College of Veterinary Medicine
Western Digital $110M Debt Financing with U.S. Bank Trust Company, National Association
Western Digital Corporation has issued a notice to redeem all $109.505 million of its outstanding 3.00% Convertible Senior Notes due 2028 on November 16, 2026. The company expects most holders to convert their notes into a combination of cash and common stock prior to the redemption date at a rate of 26.5231 shares per $1,000 principal amount. This action allows the company to settle the debt obligation and simplify its capital structure.
Dominari Holdings President Kyle Michael Wool Buys $209K of Stock
Kyle Michael Wool, President, bought 100,000 shares of Dominari Holdings Inc. at $2.02 to $2.16 a share (average $2.09) in 2 transactions, worth $209K in total between Sep 10, 2026 and Sep 11, 2026. Shares held after the trade: 4,311,828 (+1.2%).
Dominari Holdings CEO Anthony Hayes Buys $209K of Stock
Anthony Hayes, CEO, bought 100,000 shares of Dominari Holdings Inc. at $2.02 to $2.16 a share (average $2.09) in 2 transactions, worth $209K in total between Sep 10, 2026 and Sep 11, 2026. Shares held after the trade: 4,600,873 (+1.1%).
Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children aged 2 and older. This marks the first and only muscle-targeted treatment approved for SMA, representing a significant therapeutic breakthrough for the company's myostatin biology platform.
Earnings call
Sep 14, 2026, 8:00 AM ET
“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD.”
David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock
Strategy Inc repurchased 1,420,467 shares of its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC) for an aggregate price of $139.3 million. As of September 13, 2026, the company maintains a bitcoin treasury of approximately 845,050 BTC and has $2.05 billion in remaining authorization across its preferred and common stock repurchase programs.
Strive, Inc. provided an operational update disclosing the purchase of 469 bitcoin between September 8 and September 11, 2026, at an average price of $77,954 per coin. The company reported its total bitcoin holdings reached 25,000 as of September 11, 2026, alongside updates to its cash position and share count metrics.
AirJoule Technologies Signs $27M M&A Deal with Bitsink LLC
AirJoule Technologies acquired 100% of Bitsink LLC, a manufacturer of cooling and power infrastructure for AI and high-density data centers, for $18 million in cash and $9 million in common stock. The deal includes up to $40 million in additional performance-based earnout payments through 2029, significantly expanding AirJoule's footprint in the AI and HPC infrastructure market.
KeyCorp filed a formal presentation deck for the Barclays Global Financial Services Conference on September 14, 2026. The presentation includes an updated 2026 financial outlook, raising revenue growth expectations to approximately 8% and noninterest income growth to 4-5%.
Edward M. Weil, Jr. resigned from the board of directors of National Healthcare Properties, Inc. effective September 11, 2026. The company stated that his departure was not due to any disagreement regarding operations, policies, or practices.
Texas Capital Bancshares Nasdaq/NYSE Compliance Notice
Texas Capital Bancshares is voluntarily withdrawing its common and preferred stock listings from Nasdaq to transfer them to the newly formed Texas Stock Exchange (TXSE). Trading is expected to begin on the TXSE on October 8, 2026, with a subsequent ticker symbol change from TCBI to TXCP scheduled for November 9, 2026.
PBF Holding Company LLC and PBF Finance Corporation have commenced a private offering of $500 million in senior unsecured exchangeable notes due 2032. The proceeds, along with available cash, will be used to fund the full redemption of the company's outstanding 7.875% Senior Unsecured Notes due 2030. Additionally, the company disclosed it recently completed a $387 million acquisition of hydrogen production plants at its Torrance refinery and is negotiating a renewal of its revolving credit facility.
Sky Harbour Group CFO Francisco Gonzalez Buys $10.1K of Stock
Francisco Gonzalez, CFO, bought 1,000 shares of Sky Harbour Group Corp at $10.08 a share, worth $10.1K in total on Sep 11, 2026. Shares held after the trade: 711,588 (+0.1%).
Soluna Holdings announced that ERCOT has conditionally classified its 100 MW Project Dorothy campus as 'Base Load' in Batch Zero, preserving its interconnection capacity. This follows a similar classification for the company's 166 MW Project Kati, bringing its total conditionally classified base load capacity in Texas to 266 MW. The company has also submitted a request for an additional 50 MW at the Dorothy site which is currently under study.
VisionWave Holdings has been prequalified by the Liberia Petroleum Regulatory Authority (LPRA) to enter into direct negotiations for a Production Sharing Contract (PSC) in Liberia. The invitation follows a due diligence review but does not yet grant any rights to specific petroleum blocks or hydrocarbon resources. There is no assurance that negotiations will result in a definitive agreement or that the company will secure the necessary capital for future operations.
Cullinan Therapeutics and Taiho announced positive results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation-positive NSCLC. The trial met its primary endpoint, showing a statistically significant median progression-free survival of 14.5 months compared to 8.5 months for chemotherapy alone (HR 0.50).
Alpha Compute Insider Fiorenzo Villani Buys $35.5K of Stock
Fiorenzo Villani bought 7,000 shares of Alpha Compute Corp at $5.07 a share, worth $35.5K in total on Sep 9, 2026. Shares held after the trade: 22,219 (+46.0%).
Alpha Compute CEO Brittany Kaiser Buys $50K of Stock
Brittany Kaiser, CEO, bought 9,350 shares of Alpha Compute Corp at $5.35 a share, worth $50K in total on Sep 9, 2026. Shares held after the trade: 16,766 (+126.1%).
NPK International Inc. appointed James Barton as Executive Vice President, Commercial Growth & Operations, effective September 22, 2026. He succeeds Lori Briggs, who will depart from her role as Executive Vice President, Business Operations on September 14, 2026. Barton joins from Clear Water Services and brings over 20 years of experience in strategic sales and operations.
Q32 Bio appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. Both executives bring extensive experience in late-stage clinical development and regulatory strategy as the company prepares to advance bempikibart into a registration-directed program for alopecia areata in 2027.
FrontView REIT released an Investor Update deck in connection with upcoming real estate investor conferences, highlighting its 2026 investment activity and strategic growth targets. The company reported $119.3 million in year-to-date acquisitions at a 7.40% cash capitalization rate and established full-year 2026 investment guidance of $120 million. The presentation emphasizes the company's ability to drive sector-leading AFFO per share growth through retained free cash flow and accretive capital recycling.
Solid Power, Inc. published an updated investor presentation on its website and filed it as an exhibit to its 8-K. The presentation provides a company overview and strategic update as of September 2026, intended for use in meetings with investors and analysts.
Immunocore has achieved its target enrollment of 540 patients in the Phase 3 TEBE-AM clinical trial evaluating tebentafusp (KIMMTRAK) for the treatment of advanced melanoma. The trial is a registrational study, and the company expects to report topline overall survival data as early as the end of 2026.
Armata Pharmaceuticals received FDA Breakthrough Therapy designation for its AP-SA02 product candidate for the treatment of complicated S. aureus bacteremia. The designation is supported by Phase 2 data showing a 100% clinical response rate without relapse at 28 days, compared to 75% for the placebo group. This status is intended to expedite the development and review of the therapy, which could potentially become the first antibacterial treatment approved based on superiority to current standard-of-care.
Corbus Pharmaceuticals Holdings Clinical Trial Data
Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The study met its primary objectives, demonstrating statistically significant weight loss of 5% at the 60 mg dose over 12 weeks with a favorable safety profile and no evidence of weight loss plateauing. The data supports CRB-913's potential as a first-in-class oral, non-incretin obesity medicine.
Bally's $560M Debt Financing with WhiteHawk Capital Partners, LP
Bally's Corporation entered into a senior secured term loan agreement for up to $560 million, consisting of a $400 million initial commitment and a $160 million delayed draw facility. The financing, led by WhiteHawk Capital Partners, will fund pre-construction costs for the Bally's Bronx project and provide general corporate liquidity. The loans bear interest at Term SOFR plus 8.50% and mature 18 months after initial funding.
Flowserve Corporation announced that Amy B. Schwetz will resign as CFO on September 30, 2026, to join another public company. Brian Ezzell, currently VP of FP&A, Treasurer, and Investor Relations, has been appointed as the new Senior Vice President and CFO effective October 1, 2026. Ezzell will receive a base salary of $625,000 and a target annual long-term incentive award of $1.6 million starting in 2027.
Hain Celestial Group Divestiture to Aurelius for $323M
Hain Celestial has entered into a definitive agreement to sell its International business operating in the UK, Ireland, and Europe to affiliates of private equity firm AURELIUS for approximately $323.2 million (£238.5 million). The transaction includes brands such as Ella’s Kitchen, Joya, and Hartley’s, with net proceeds intended to reduce the company's indebtedness. Closing is contingent on regulatory approvals and an amendment to the company's credit agreement to extend its December 2026 maturity date.
Value
$323M
Counterparty
AURELIUS
Earnings call
Sep 14, 2026, 8:00 AM ET
“Fiscal 2026 was a pivotal year for Hain. We simplified our portfolio, reduced debt, significantly improved free cash flow and exited the year with improving momentum across the business.”
Alison Lewis, President and CEO
“Assuming we successfully complete the transaction announced today to sell our International business and that we reach an agreement with our lenders to extend of our December debt maturity, we would expect to become a more focused North American company with leading brands in attractive categories and a streamlined operating model.”